Stents

Cre8™EVO, Stent sin polímero liberador de Amphilimus

Estudios en animales

  • Claudio Moretti et ali (2012) Cre8™ coronary stent: preclinical in vivo assessment of a new generation polymer-free DES with Amphilimus™ formulation EuroIntervention 7: 1087- 1094

Estudios

  • Rozemeijer et al. (2018) The ReCre8 Trial: Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent: (ReCre8) A Multicenter, Non-Inferiority Trial
  • Godino et al. (2017) Polimer- free amphilimus-eluting versus biodegradable polimer biolimus-eluting stentin patients with and without diabetes mellitus. International Journal of Cardiology, 231, 54-60
  • Sardella et al. (2017) Clinicals outcomes with reservoirs-based polymer-free amphilimus-eluting stents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 Registry Catheterizaton and Cardiovascular Interventions, 1- 8
  • Godino et al (2017) Midterm and one- year outcome of amphilimus polimer-free drug-eluting stent in patients needing short dual antiplatelet therapy: the ASTUTE Registry. International Journal of Cardiology, 231, 54- 60
  • Stella et al. (2017). Rationale and design of Amphilimus Sirolimus-eluting stents versus Zotarolimus-eluting stents in all-comers requiring percutaneous coronary intervention (ReCre8): A Multicenter Randomized Clinical Trial. Catheter Cardiovascular Inerventions, 1- 7.
  • Colombo et al. (2016) Midterm and one- year outcome of amphilimus polimer-free drug-eluting stent in diabetes mellitus patients: the ASTUTE Registry. International Journal of Cardiology, 214, 113- 120.
  • Romaguera et al.(2016) A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus The RESERVOIR Clinical Trial. Journal American College of Cardiology, Cardiovascular Interventions, 9, 42- 50
  • Colombo et al. (2015) Clinical Outcomes of Real-World Patients Treated With an Amphilimus Polymer-Free Stent Versus New Generation Everolimus-Eluting Stents (2015). Catheterizaton and Cardiovascular Interventions, DOI 10.1002/ccd.
  • Banai et al. (2014) Polymer-free drug-eluting stent in unselected patient population: A single center experience. Cardiovascular Revascularization Medicine, 15, 350- 353
  • Prati et al. (2014) Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: The DEMONSTRATE study. International Journal of Cardiology, 176, 904- 909
  • Carrié et al. (2012) A Multicenter Randomized Trial Comparing Amphilimus- With Paclitaxel-Eluting Stents in De Novo Native Coronary Artery Lesions. Journal American College of Cardiology, 59, no. 15, 1371-1376

Editoriales Gerenalistas

  • Stella et al. (2016) PCI in patients with diabetes: role of the Cre8 Drug- Eluting Stent. Radcliffe Cardiology, 11:1- 8 
  • Carrie (2016) Advances with polimer-free amphilimus-eluting stents. Minerva Cardiologica, 64 (3): 339- 353 
  • Mehran et al. (2015) Patient-tailored DES Choice- A solution for patients with diabetes. Radcliffe Cardiology, 10(3): 158- 61
  • Romaguera et al. (2014) Polime- free Amphilimus-eluting stents in patients with diabetes mellitus. Minerva Cardiologica, 62: 421-26
  • Nikam et al. (2014) Advances in Stent Technologies and their effect on clinical efficacy and Safety. Dove Press, 7: 165-178
  • Stella et al. (2014) Meeting the Unmet- The Cre8 Polimer- Free DES technology. Radcliffe Cardiology, 9(3): 184-9
  • Mountfort (2014) Cre8™ Unique Technology in Challenging Daily Practice. Radcliffe Cardiology, 9 (3);:180-3
  • Sangiorgi et al. (2012) Repetia Iuvant: why another paper on a new stent is important. EuroInervention, 7:1014-1017

Laser Coronario

Stents subexpandidos. Restenosis intrastent

  • Mehran et al. Circulation, 1997; 96: 2183- 2189
    Treatment of in- stent- restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone.
  • Köster et al. JACC, 1999; Vol. 34: 25- 32
    Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial. The Laser Angioplasty of Restenoted Stents (LARS).
  • Mehran et al. Circulation, 2000; 101: 2484-2489
    Treatment of in- stent- restenosis with excimer laser coronary angioplasty versus rotational atherectomy: Comparative mechanisms and results.
  • Giri et al. Catheterization Cardiovascular Intervention, 2001; Vol. 52: 24- 34
    Clinical an angiographic outcome in the laser angioplasty for restenotic stents (LARS) multicenter registry.
  • Bilodeau et al. Catheterization and Cardiovascular Intervention, 2008; Vol. 71: 803- 807
    Hight energy excimer laser to treat coronary in-stent restenosis in an underexpanded stent.
  • EuroIntervention, 2011; Vol 7: 400-407
    How should I treat severe calcific coronaryartery.
  • Nishino et al. Journal Invasive Cardiology, 2012; Vol. 24 (10): 478-483
    Differences in optical coherence tomographic findings and clinical outcomes between excimer laser and cutting ballon angioplsty for focal in-stent-restenosis lesions.
  • Colombo et al. Cardiovascular Revascularization Medicine, 2014; Vol.15: 08-12
    Excimer Laser Lesion Modification to expand non-Dilatable stents: The ELEMENT Registry.
  • Yin et al., JACC Cardiovascular Intervention, 2015; 8: e137-139
    Excimer laser angioplasty- facilitated fracturing of napkin-ring peri-stent calcium in a chronically underexpand stent: documentation by optical coherence tomography. JACC
  • Ashikaga et al. Catheterization Cardiovascular Intervention, 2015; Vol. 86, (5): 946-949
    The effectiveness of excimer laser coronary atherectomy with contrast medium for underexpanded stent: The findings of optical frequency domain imaging.
  • Karacsonyi et al. JACC, 2016; Vol. 9: No. 15
    Laser coronary atherectomy during contrast injection for treating an unexpanded stent.
  • Hirose et al. Lasers in Medical Science, 2016; 31: 1691- 1696
    Treatment of in- stent- restenosis with excimer laser coronary angioplasty: benefits over scoring balloon angioplasty alone.
  • Andreou et al. Science Direct, 2017; 58:303- 305
    Excimer laser-facilitated stent expansión: The effect of contrast enhancement.
  • Lee et al. JACC, 2017; Vol. 69 (11): 478-483
    The efectiveness of excimer laser angioplasty to treat coronary in- stent restenosis with peri-stent as assessed by optical coherence tomography.
  • Nakamura et al. International Heart Journal, 2018; Vol. 59: 1-2 Clinical outcomes after treatment with Elca for in-stent restenosis of DES.
  • Ichimoto et al. International Heart Journal, 2018; Vol. 59: 14-20. Long- term clinical outcomes after treatment with excimer laser atherectomy for in-stent restenosis of DES.

 

Trombos

  • O’ Kane et al. Cardiovascular Intervention and Therapeutics (2014)
    Contemporary therapy of intracoronary thrombus: laser and bioresorbable scaffold
  • Niccoli et al. The American Journal of Cardiology, 2013
    Case-Control Registry of Excimer Laser Coronary Angioplasty Versus Distal Protection Devices in Patients with Acute Coronary Syndromes due to saphenous Vein Graft Disease.
  • Shishikura et al. Circulation Journal, June 2013; Vol.77: 1445-1452
    Vaporizing Thrombus With Excimer Laser Before Coronary Stenting Improves Myocardial Reperfusion in Acute Coronary Syndrome.
  • O’Kane et al. Heart on line, 2013; 127: 98-102
    Strategies for the management of massive intracoronary thrombus in acute myocardial infarction
  • Ambrosini et al. International Journal of Cardiology, 2008; 127: 98-102
    Excimer Laser in Acute Myocardial Infarction: Single center experience on 66 patients.

 

Lesiones Complejas y CTO

  • Mohandes et al. Cardiovascular Revascularization Medicine, 2017; 18: S2-S6
    Percutaneous coronary interventionof chronically occluded saphenous vein grafts using excimer laser atherectomy as an adjuvant therapy.
  • Ambrosini et al. Cardiovascular Revascularization Medicine 2015,; Vol 16 (3),2015, 141-146
    Early outcome of high energy laser facilitated coronary angioplasty on hard and complex calcified an balloon resistant coronary lesions, LEONARDO Study.
  • Azzalini. International Heart Journal and Cardiovascular Intervention 2014; Vol. 55: 546-549
    Laser Atherectomy for Balloon failure in Chronic Total Occlusion.
  • Bilodeau et al. Catheterization and Cardiovascular Intervention 2004; Vol. 62: 155-161
    Novel use of a high-energy Excimer Laser Catheter for Calcified and Complex Coronary Artery Lesions
  • Serruys et al. European Heart Journal, 2000; 21, 1797-1805
    Total occlusion trial with angioplasty by using laser guidewire. The TOTAL Trial.
  • Bittl et al. Circulation, 1992; Vol. 86 (1): 71- 80
    Excimer laser- facilitated coronary angioplasty. Relative risk analysis of acute and follow-up results in 200 patients.

 

Otros

  • Deckelbaum et al. JACC, 1995; Vol. 26: 1264-1269
    Effect of intracoronary saline infusión on disection during excimer laser coronary angioplasty: a randomizaed trial. Percutaneous Excimer Laser Coronary angioplasty (PELCA).
  • Mintz et al. Circulation1995; 92: 3408- 3414
    Mechanism of lumen enlargement after excimer laser coronary angioplasty. An intravascular ultrasound study.

Láser vascular periférico

  • Garcia- Garcia et al., 2017. Intravascular ultrasound assessment of the effect of laser energy on the arteria wall during the treatment of femoro-popliteal lesions: CliRpath excimer laser system to enlarge lumen openings (CELLO) registry study. Inernational Journal Cardiovascular Imaging, 34 (3): 345-352
  • Mallios et al. (2017), Laser Atherectomy for the treatment of peripheral arterial disease, Annals of Vascular surgery, 44; 269-276
  • Argueta et al. (2016), A retrospective analysis of laser endartherectomy assisted balloon angioplasty for popliteal and infrapopliteal peripheral arterial disease. International Journal of Cardiology, 225; 87-90
  • Walker et al.(2015), Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR JACC Cardiovascular Interventions, 8(1 Part A), 92-101.
  • Lüdtke et al. (2014) Transpopliteal Balloon-Assisted Excimer–Laser Atherectomy for the Treatment of Chronic Femoropopliteal Occlusions: Feasibility and initial results. Clinical Medicine Insights: Cardiology, 8(s2) 23–28
  • Sherif Sultan 2013, Cool Excimer Laser-Assisted Angioplasty (CELA) and Tibial Balloon Angioplasty (TBA) in Management of Infragenicular Arterial Occlusion in Critical Lower Limb
  • Ischemia (CLI). Vascular and Endovascular Surgery, 1- 13
  • Dave RM et al., 2009, Excimer Laser Recanalization of femoropopliteal lesions and 1-year patency: results of the CELLO Registry. Journal Endovascular Therapies, 16 (6), 665-675 Tony S. Das et al. (2009). Excimer Laser- assisted angioplasty for Infrainguinal Artery Disease. Journal of Endovascular Therapy 16 (2), II98-II104
  • Stoner et al. (2007), Mid-term results with laser atherectomy in the treatment of infrainginal occlusive disease. Journal of Vascular Surgery, 289-295
  • Lair J.R. et al. (2006), Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. Journal Endovascular Therapies, 13(1), 1-11.
  • Bosiers M. et al. (2005), Excimer laser-assisted angioplasty for critical limb ischemia: results of the LACI Belgium study. European Journal Vascular and Endovascular Surgery, 29, 613-619

Gore Septal Occluder Cardioform

2019

  • Agasthi P, Kolla KR, Yerasi C, et al. Are we there yet with patent foramen ovale closure for secondary prevention in cryptogenic stroke? A systematic review and meta-analysis of randomized trials. SAGE Open Medicine 2019;7.
  • Agdamag AC, Gomez JM, Collado FM, Kavinsky C. Patent foramen ovale and ascending aortic aneurysm causing the platypnea-orthodeoxia syndrome. Baylor University Medical Center Proceedings 2019;32(2):242-244.
  • Al Danaf J, Saidi A, Smith B, Tandar Patent foramen ovale closure using Cardioform Occluder Device through the right internal jugular vein for primary prevention (first in man): importance of a multidisciplinary team. Journal of Structural Heart Disease 2019;5(2):43-47.
  • Alkhouli M, Sievert H, Rihal CS. Device embolization in structural heart interventions: incidence, outcomes, and retrieval techniques. JACC: Cardiovascular Interventions 2019;12(2):113-126.
  • Alkhouli M, Alqahtani F, Siddoway D, Ellison M. Acute ballooning of a Cardioform Septal Occluder during percutaneous closure of an iatrogenic atrial septal defect. Structural Heart
    • 2019;3(3):258-259.
  • Alkhouli M, Sievert H, Holmes DR. Patent foramen ovale closure for secondary stroke European Heart Journal. In press.
  • Alrayes H, Parikh S. Paradoxical coronary embolus- a rare cause of ST-elevation myocardial infarction. Case Reports 2019;32.
  • Anantha-Narayanan M, Reddy YNV, Malik U, et al. Device closure of patent foramen ovale—is it time to update the guidelines? Structural Heart 2019;3(1):4-10.
  • Anderson JH, Cabalka AK. Intracardiac echocardiography. In: Butera G, Chessa M, Eicken A, Thomson JD, eds. Atlas of Cardiac Catheterization for Congenital Heart Disease. Cham, Switzerland: Springer International Publishing, AG; 2019;41:361-367.
  • Anderson JH, Migliati E, Adamson T, Moats J, Hua K, Inglessis I. Perforating the GORE® CARDIOFORM Septal Occluder and Atrial Septal Defect Occluder to Gain Access to the Left Atrium. Presented at the Society for Cardiovascular Angiography & Interventions 2019 Scientific Sessions; May 19-22, 2019; Las Vegas, Catheterization & Cardiovascular Interventions 2019;93(S2):S223-S224. IV-02.
  • Boudoulas KD, Marmagkiolis K, Boudoulas H. Atrial septal defect sizing and transcatheter closure. Cardiology 2019;142(2):105-108.
  • Dahal K, Yousuf A, Watti H, et al. Who benefits from percutaneous closure of patent foramen ovale vs medical therapy for stroke prevention? In-depth and updated meta-analysis of randomized trials. World Journal of Cardiology 2019;11(4):126-136.
  • Della Rocca DG, Horton R, Mohanty S, et al. First experience of left atrial appendage occlusion with Cardioform Septal Occluder in patients with left atrial appendage residual patency or complex anatomy. Presented at the ACC.19 68th Annual Scientific Session and Expo; March 16-18, 2019; New Orleans, LA. Journal of the American College of Cardiology 2019;73(9)Supplement 1:1294. Presentation Number: 1250-011.
  • Diener HC, Grau A, Baldus S. Cryptogenic stroke and patent foramen ovale (abridged and translated version). Neurological Research & Practice 2019;1:1.
  • Elgendy AY, Elgendy IY, Mojadidi MK, et al. New-onset atrial fibrillation following percutaneous patent foramen ovale closure: a systematic review and meta-analysis of randomised trials. EuroIntervention 2019;14(17):1788-1790.
  • Favilla CG, Messé SR. Paradoxical embolic stroke: diagnosis and management. In: Kitchens CS, Kessler CM, Konkle BA, Streiff MB, Garcia DA, eds. Consultative Hemostasis & 4th ed. Philadelphia, PA. Elsevier; 2019;39:802-810.
  • Frisoli TM, Greenbaum A, O’Neill WW, Wang DD, Eng M. Percutaneous repair of mitral valve leaflet perforation. JACC: Cardiovascular Interventions 2019;12(2):210-213.
  • Giblett JP, Abdul-Samad O, Shapiro LM, Rana BS, Calvert Patent foramen ovale closure in 2019. Interventional Cardiology 2019;14(1):34-41.
  • Giordano M, Gaio G, Santoro G, et al. Patent foramen ovale with complex anatomy: comparison of two different devices (Amplatzer Septal Occluder device and Amplatzer PFO Occluder device 30/35). International Journal of Cardiology 2019;279:47-50.
  • Gössl M. Closure of patent foramen ovale using a Cardioform Septal Occluder. Structural Heart Cases: A Color Atlas of Pearls and Pitfalls. 1st ed. Philadelphia, PA: Elsevier; 2019:234-235.
  • Hildick-Smith D, Turner M, Shaw L, et al. Evaluating the cost-effectiveness of percutaneous closure of a patent foramen ovale versus medical management in patients with a cryptogenic stroke: from the UK payer perspective. Journal of Medical Economics 2019;22(2):131-139.
  • Horlick E, Kavinsky CJ, Amin Z, et al. SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: The American Academy of Neurology affirms the value of this statement as an educational tool for Catheterization & Cardiovascular Interventions 2019;93(5):859-874.
  • Kim AY, Jung SY, Chang JY, Jung JW, Choi Early to mid-term follow-up outcomes of percutaneous closure of atrial septal defects using recent generation devices: a single-center experience. Korean Circulation Journal 2019;49(4):326-335.
  • Köhrmann M, Schellinger PD, Tsivgoulis G, Steiner Patent foramen ovale: story closed?
    • Journal of Stroke 2019;21(1):23-30.
  • Kubicki R, Fingerhut K, Uhl M, et al. Wire-frame integrity of patch-like Gore devices following atrial septal defect closure. Catheterization & Cardiovascular Interventions 2019;93(4): E238-
  • Madhkour R, Meier B. PFO and cryptogenic stroke: when should it be closed? Revista Espanola de Cardiologia (English ed.). 2019;72(5):369-372.
  • Makhija RR, Palaniswamy C, Aronow WS. Closure of patent foramen ovale for secondary prevention of cryptogenic stroke: current perspectives. Archives of Medical Science 2019;3(15):1-4.
  • Mawri S, Fuller B, Szymanski T, Wang DD, Alaswad K. Percutaneous closure of post-traumatic pulmonary arteriovenous fistula. Presented at the ACC.19 68th Annual Scientific Session and Expo; March 16-18, 2019; New Orleans, LA. Journal of the American College of Cardiology 2019;73(9)Supplement 1:2748. Presentation Number: 1261-166.
  • Michel P, Villablanca PA, Ranka S, Lemor A, Jain T, Ramakrishna H. Patent foramen ovale and risk of cryptogenic stroke – analysis of outcomes and perioperative implications. Journal of Cardiothoracic & Vascular Anesthesia. In
  • Moon J, Kim M, Oh PC, et al. Residual shunt after patent foramen ovale device closure in patients with cryptogenic stroke: serial bubble contrast transesophageal echocardiography Journal of Stroke & Cerebrovascular Diseases 2019;28(2):347-353.
  • Nasir UB, Qureshi WT, Jogu H, et al. Updated meta-analysis of closure of patent foramen ovale versus medical therapy after cryptogenic stroke. Cardiovascular Revascularization Medicine: Including Molecular Interventions 2019;20(3):187-193.
  • O’Byrne ML, Levi DS. State-of-the-art atrial septal defect closure devices for congenital
    • Interventional Cardiology Clinics 2019;8(1):11-21.
  • Praz F, Siontis GCM, Xhigoli A, et al. Percutaneous patent foramen ovale closure during live case demonstrations. Catheterization & Cardiovascular Interventions 2019;93(5):982-988.
  • Pristipino C, Sievert H, D’Ascenzo F, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. EuroIntervention 2019;14(13):1389-1402.
  • Rawlingson E, Forshaw N. Interventional Cardiology. In: Cote CJ, Lerman J, Anderson B, eds. A Practice of Anesthesia for Infants and Children. 6th ed. Philadelphia, PA: Elsevier, Inc; 2019; (22):520-533.e3.
  • Rigatelli G, Nghia NT, Zuin M, Conte L, D’Elia K, Nanjundappa A. Very long-term outcomes of transcatheter secundum atrial septal defect closure using intracardiac echocardiography without balloon sizing. Clinical Radiology. In
  • Sato J, Kato A, Takeda S, Nishikawa H. Case report: atrioventricular block after transcatheter atrial septal closure using the Figulla® Flex II ASD occluder. Catheterization & Cardiovascular Interventions 2019;93(5):E298-E301.
  • Scholz EP, Seidensaal K, Naumann P, André F, Katus HA, Debus J. Risen from the dead: cardiac stereotactic ablative radiotherapy as last rescue in a patient with refractory ventricular fibrillation storm. HeartRhythm Case Reports. In
  • Shah R, Khan B, Rawal A, Ashraf F, Berzingi C, Rashid A network meta-analysis comparing safety and efficacy of various devices for patent foramen ovale closure in patients with cryptogenic stroke. Presented at the ACC.19 68th Annual Scientific Session and Expo; March 16-18, 2019; New Orleans, LA. Journal of the American College of Cardiology 2019;73(9)Supplement 1:1128. Presentation Number: 1106-062.
  • Schubert S, Nordmeyer J, Peters B, Kramer P, Berger Atrial septal defect closure (ASD and PFO) without fluoroscopy in both paediatric and adult patients-19 years of experience. Presented at the 53rd Annual Meeting of the Association for European Paediatric and Congenital Cardiology; May 15-18, 2019; Seville, Spain. Cardiology in the Young 2019;29(Supplement):S43-S44.
    • MP1-7.
  • Sigler M, Foth R, Eildermann K, Paul Histopathology of 56 human explanted atrial septal defect (ASD) closure devices. Presented at the 53rd Annual Meeting of the Association for European Paediatric and Congenital Cardiology; May 15-18, 2019; Seville, Spain. Cardiology in the Young 2019;29(Supplement):S35.
  • Tobis Patent foramen ovale: what cardiologists and neurologists need to know.
    • Catheterization & Cardiovascular Interventions 2019;93(6):1085-1086.
  • Ungerleider GD, Yarrabolu TR, Stewart RD. Critical heart disease in infants and children atrial septal defects. In: Ungerleider RM, McMillan KN, Jacobs JP, Meliones JN, Cooper DS, eds. Critical Heart Disease in Infants and Children. 3rd ed. Philadelphia, PA: Elsevier, Inc; 2019;47:572-586.e1.
  • Vitarelli A. Patent foramen ovale: Pivotal role of transesophageal echocardiography in the indications for closure, assessment of varying anatomies and post-procedure follow-up. Ultrasound in Medicine & Biology. In
  • Volpi JJ, Ridge JR, Nakum M, Rhodes JF, Sondergaard L, Kasner SE. Cost-effectiveness of percutaneous closure of a patent foramen ovale compared with medical management in patients with a cryptogenic stroke: From the US payer perspective. Journal of Medical Economics. In press.
  • Wang TKM, Wang MTM, Ruygrok Patent foramen ovale closure versus medical therapy for cryptogenic stroke: meta-analysis of randomised trials. Heart, Lung and Circulation 2019;28(4):623-631.
  • Wang DD, Geske JB, Choi AD, et al. Interventional imaging for structural heart disease: challenges and new frontiers of an emerging multi-disciplinary field. Structural Heart 2019;3(3):187-200.

2018

  • Abdelaziz HK, Saad M, Abuomara HZ, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: a meta-analysis of randomized trials. Catheterization & Cardiovascular Interventions 2018;92(1):176-186.
  • Abdulsalam N, Goldsweig AM. Porous CARDIOFORM Septal Occluder balloons within the right atrial JACC: Cardiovascular Interventions 2018;11(14):e117-e118.
  • Abo-salem E, Chaitman B, Helmy T, Boakye EA, Alkhawam H, Lim M. Patent foramen ovale closure versus medical therapy in cases with cryptogenic stroke, meta-analysis of randomized controlled trials. Journal of Neurology 2018;265(3):578-585.
  • Ahmad Y, Howard JP, Arnold A, et al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. European Heart Journal 2018;39(18):1638-1649.
  • Akobeng AK, Abdelgadir I, Boudjemline Y, Hijazi ZM. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: a systematic review and meta-analysis of randomized controlled trials. Catheterization & Cardiovascular Interventions 2018;92(1):165-173.
  • Al Danaf J, Wever-Pinzon J, Tandar A, et al. Cardiopulmonary presentation of a patient with XXXY Syndrome. Presented at the American College of Cardiology’s 67th Annual Scientific Session and Expo (ACC.18); March 10 – March 12, 2018; Orlando, FL. Journal of the American College of Cardiology 2018;71(1)Supplement:2444. Presentation Number: 1241-122.
  • Alkhouli M, Campsey DM, Higgins L, Badhwar V, Diab A, Sengupta Transcatheter closure of a sinus venosus atrial septal defect via transhepatic access. JACC: Cardiovascular Interventions 2018;11(14):e113-e115.
  • Alvarez C, Siddiqui WJ, Aggarwal S, Hasni SF, Hankins S, Eisen H. Reduced stroke after transcatheter patent foramen ovale closure: a systematic review and meta-analysis. American Journal of the Medical Sciences 2018;356(2):103-113.
  • Andersen MM, Zhao DXM. Percutaneous post-myocardial infarction ventricular septal rupture closure: a review. Structural Heart 2018;2(2):121-126.
  • Ando T, Holmes AA, Pahuja M, et al. Meta-analysis comparing patent foramen ovale closure versus medical therapy to prevent recurrent cryptogenic stroke. American Journal of Cardiology 2018;121(5):649-655.
  • Bechis MZ, Rubenson DS, Price MJ. Transcatheter tricuspid and mitral valve edge-to-edge repair: the double double orifice. CASE: Cardiovascular Imaging Case Reports 2018;2(5):164-173.
  • Bhatt J, Castro M. High output heart failure secondary to a coronary caval fistula and patent foramen ovale. Presented at the American College of Cardiology’s 67th Annual Scientific Session and Expo (ACC.18); March 10 – March 12, 2018; Orlando, FL. Journal of the American College of Cardiology 2018;71(1)Supplement:2384. Presentation Number: 1191-156.
  • Blankenship JC. PFO closure: where are the neurologists? Catheterization & Cardiovascular Interventions 2018;92(1):187-188.
  • Carroll JD. The spectrum of PFO closure devices: similarities and meaningful differences. Available from TCTMD Web site. https://tctmd.com/slide/spectrum-pfo-closure-devices- similarities-and-meaningful-differences . Published June 23, 2018. Accessed September 4, 2018.
  • Chatterjee A, Hillegass WB. Patent foramen ovale closure for cryptogenic stroke: effective, but only in select patients. Catheterization & Cardiovascular Interventions 2018;92(1):174-175.
  • Chezar-Azerrad C, Assali A, Vaknin-Assa H, Shapira Y, Eisen A, Kornowski R. Iatrogenic atrial septal defect post mitral valve in valve implantation. Cardiovascular Revascularization Medicine 2018;19(8):82-85.
  • Collado FMS, Poulin MF, Murphy JJ, Jneid H, Kavinsky CJ. Patent foramen ovale closure for stroke prevention and other disorders. Journal of the American Heart Association 2018;7(12):e007146.
  • Corciu A, De Marco F, Testa L, Bedogni Feasibility and safety/efficacy profile of the percutaneous patent foramen closure: NobleStitch EL vs. other devices. Thirtieth Annual Symposium Transcatheter Cardiovascular Therapeutics (TCT); September 21-25, 2018; San Diego, CA. Journal of the American College of Cardiology 2018;72;13(Supplement B):B223. TCT-555.
  • Diener H, Gerloff C, Thaler DE, Wöhrle J. Closure of patent foramen ovale and cryptogenic stroke: unresolved issues. Current Neurology & Neuroscience Reports 2018;18(12):92.
  • De Rosa S, Sievert H, Sabatino J, Polimeni A, Sorrentino S, Indolfi C. Percutaneous closure versus medical treatment in stroke patients with patent foramen ovale: a systematic review and meta-analysis. Annals of Internal Medicine 2018;168(5):343-350.
  • Desai M, Parekh P, Shakhatreh M, Foerst J, Yeaton Use of a cardiac septal occluder for the closure of a benign bronchoesophageal fistula. VideoGIE 2018;3(7):203-204.
  • Faccini A, Butera G. Atrial septal defect (ASD) device trans-catheter closure: limitations. Journal of Thoracic Disease 2018;10(Supplement 24):S2923-S2930.
  • Fathallah M, Krasuski RA. A multifaceted approach to pulmonary hypertension in adults with congenital heart disease. Progress in Cardiovascular Diseases 2018;61(3-4):320-327.
  • Favilla CG, Messé SR. New data support patent foramen ovale closure after stroke. Stroke
    • 2018;49(1):262-264.
  • Feldman DN, Weinberger J, Elmariah S. Device closure of patent foramen ovale in patients with cryptogenic stroke: the tide has turned. Journal of the American College of Cardiology 2018;71(20):2343-2345.
  • Fisher M, Hill JA. Ischemic stroke mandates cross-disciplinary collaboration. Circulation
    • 2018;137(2):103-105.
  • Fortuni F, Crimi G, Leonardi S, et al. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events. Journal of Cardiovascular Medicine 2018;19(7):373-381.
  • Gaspardone A, De Marco F, Sgueglia GA, et al. Novel percutaneous suture-mediated patent foramen ovale closure technique. Early results of the NobleStitch EL Italian Registry. Eurointervention 2018;14(3):e272-e279.
  • Ha KS, Choi JY, Jung SY, et al. A novel double snare technique to retrieve embolized septal and left atrial appendage occluders. Journal of Interventional Cardiology 2018;31(5):685-692.
  • Hainstock MR. Congenital heart disease. In: Ragosta M, ed. Textbook of Clinical Hemodynamics. 2nd Ed. Philadelphia, PA: Elsevier 2018;11: 249-269.
  • Hakeem A, Cilingiroglu M, Katramados A, et al. Transcatheter closure of patent foramen ovale for secondary prevention of ischemic stroke: quantitative synthesis of pooled randomized trial data. Catheterization & Cardiovascular Interventions 2018;92(6):1153-1160.
  • Ing F, Sullivan P, Takao Catheter device therapies for heart failure. In: Jefferies JL, Chang AC, Rossano JW, Shaddy RE, Towbin JA, eds. Heart Failure in the Child and Young Adult: From Bench to Bedside. Philadelphia, PA: Elsevier; 2018;46:583-622.
  • Jalal Z, Hascoët S, Gronier C, et al. Long-term outcomes after percutaneous closure of ostium secundum atrial septal defect in the young: a nationwide cohort JACC: Cardiovascular Interventions 2018;11(8):795-804.
  • Jung SY, Choi Transcatheter closure of atrial septal defect: principles and available devices.
    • Journal of Thoracic Disease 2018;10(Supplement 24):S2909-S2922.
  • Kasner SE, Kase CS, Turan TN, et al; REDUCE Study Investigators. Characterization of recurrent strokes with and without patent foramen ovale closure. Journal of the American College of Cardiology 2018;72(20):2542-2544.
  • Kasner SE, SøndergaardL, Rhodes J, et al. Consistency of efficacy of PFO closure in the Gore Reduce Trial. Presented at the American Heart Association/American Stroke Association 2018 International Stroke Conference and State-of-the-Science Stroke Nursing Symposium; January 23-26, 2018; Los Angeles, CA. Stroke 2018;49(Supplement 1). Abstract
  • Kerut EK, Campbell WF, Hall ME, McMullan MR. Identification of candidates for PFO closure in the echocardiography laboratory. Echocardiography 2018;35(11):1860-1867.
  • Kim M, Kim S, Moon J, et al. Effect of patent foramen ovale closure for prevention on recurrent stroke or transient ischemic attack in selected patients with cryptogenic stroke. Journal of Interventional Cardiology 2018;31(3):368-374.
  • Kretschmar O, Grohmann J, Bertram H, et al. New-onset of migraine and nonmigraine headache attacks after percutaneous device-closure of atrial septal defect in children: a prospective multicenter trial. Presented at the 50th Annual Meeting of the German Society for Pediatric Cardiology; February 17-20, 2018; Leipzig, Germany. Thoracic & Cardiovascular Surgeon 2018;66.
  • Kuijpers T, Spencer FA2, Siemieniuk RAC, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ 2018;362:k2515.
  • Lattanzi S, Brigo F, Cagnetti C, Di Napoli M, Silvestrini M. Patent foramen ovale and cryptogenic stroke or transient ischemic attack: to close or not to close? A systematic review and meta- analysis. Cerebrovascular Diseases 2018;45(5-6):193-203.
  • Lee PH, Song J-K, Kim JS. Reply: Cryptogenic stroke and patent foramen ovale. Ready for prime time? Journal of the American College of Cardiology 2018;72(10):1185-1186.
  • Lee PH, Song J-K, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: The DEFENSE-PFO Trial. Journal of the American College of Cardiology 2018;71(20):2335-2342.
  • Leppert MH, Poisson SN, Carroll JD, et al. Cost-effectiveness of patent foramen ovale closure versus medical therapy for secondary stroke prevention. Stroke 2018;49(6):1443-1450.
  • Luc JGY, Bakar SN, Kiaii B, Sridhar K. Thrombus in a hypercoagulable patient following patent foramen ovale closure wth the Gore Septal Occluder. Short communication. JACC: Cardiovascular Interventions 2018;11(11):1108-1109.
  • McQuillan C, Gray A, Kearney A, Menown IBA. Advances in clinical cardiology 2017: a summary of key clinical trials. Advances in Therapy 2018;35(7):899-927.
  • Madhkour R, Meier B. Patent foramen ovale closure, a contemporary review. Structural Heart
    • 2018;2(2):114-120.
  • Malik M, Baig M, Cinquegrani M. Platypnea-Orthodeoxia Syndrome secondary to intra-atrial shunt: successful outcome after percutaneous device closure. Presented at the American College of Cardiology’s 67th Annual Scientific Session and Expo (ACC.18); March 10 – March 12, 2018; Orlando, FL. Journal of the American College of Cardiology 2018;71(1)Supplement:2212. Presentation Number: 1108-171.
  • Mir H, Siemieniuk RAC, Ge LC, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open 2018;8(7):e023761.
  • Mojadidi MK, Mahmoud AN, Patel NK, Elgendy IY, Meier B. Cryptogenic stroke and patent foramen ovale: ready for Prime Time?. Journal of the American College of Cardiology 2018;72(10):1183-1185.
  • Mojadidi MK, Zaman MO, Elgendy IY, et al. Cryptogenic stroke and patent foramen
    • Journal of the American College of Cardiology 2018;71(9):1035-1043.
  • Najib K, Heckle M, Goubran S, Mehta R, Goswami R, Khouzam RN. Paradoxical emboli following a pulmonary embolus in the presence of a patent foramen ovale. Annals of Translational Medicine 2018;6(1).
  • Nakajima Y, Kar S. First experience of the usage of a GORE CARDIOFORM Septal Occluder device for treatment of a significant residual commissural mitral regurgitation jet following a MitraClip procedure. Catheterization & Cardiovascular Interventions 2018;92(3):607-610.
  • Nielsen-Kudsk J, Andersen A, Andersen G, et al; REDUCE Investigators. Atrial fibrillation after closure of persistent foramen ovale in the REDUCE clinical trial. European Heart Journal 2018;39:1340.
  • Nikitczuk J, Love B. The ruler test: a novel adjunctive tool to aid in percutaneous device closure of atrial septal defects with Gore Cardioform Septal Occluder. Presented at the Society for Cardiovascular Angiography & Interventions’ 41st Annual Scientific Sessions; April 25-28, 2018; San Diego, CA. Catheterization & Cardiovascular Interventions 2018;91(Supplement 2):S136. VI-29.
  • Ntaios G, Papavasileiou V, Sagris D, et al. Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack: updated systematic review and meta-analysis. Stroke 2018;49(2):412-418.
  • Oh PC, Kang WC, Moon J, Kim M, Yu Residual shunt after patent foramen ovale device closure in patients with cryptogenic stroke: serial bubble contrast transesophageal echocardiography data. Presented at the Thirtieth Annual Symposium Transcatheter Cardiovascular Therapeutics (TCT); September 21-25, 2018; San Diego, CA. Journal of the American College of Cardiology 2018;72;13(Supplement B):B100-B101. TCT-242.
  • Pasceri V, Pelliccia F, Bressi E, et al. Net clinical benefit of patent foramen ovale closure in patients with cryptogenic stroke: meta-analysis and meta-regression of randomized trials. International Journal of Cardiology 2018;266:75-80.
  • Piccolo R, Franzone A, Siontis GCM, et al. Patent foramen ovale closure vs. medical therapy for recurrent stroke prevention: evolution of treatment effect during follow-up. International Journal of Cardiology 2018;255:29-31.
  • Pineda M, Harrison K. Treatment options for recurrent thromboembolism in patients with cryptogenic cerebrovascular events: medical therapy versus device closure or surgical repair of patent foramen ovale. In: Topaz O, ed. Cardiovascular Thrombus. From Pathology and Clinical Presentations to Imaging, Pharmacotherapy and Interventions.1st ed. Cambridge, MA: Academic Press; 2018;35:505-514.
  • Prieto LR. Outcomes after device closure of atrial septal defect in children: the present is good, is the future brighter? JACC: Cardiovascular Interventions 2018;11(8):805-807.
  • Putot A, Laborde C, Fichot M, et al. Falls and delirium: Platypnea-Orthodeoxia
    • American Journal of Medicine 2018;131(3):250-252.
  • Qiu B, Cai Y, Wang D, Lin J, Fan Closure versus medical therapy for patent foramen ovale in patients with cryptogenic stroke: an updated meta-analysis of randomized controlled trials.
    • Journal of Stroke & Cerebrovascular Diseases 2018;27(12):3463-3472.
  • Reinthaler M, Ozga A, Sinning D, et al. Revival of transcatheter PFO closure: a meta-analysis of randomized controlled trials – impact of shunt size and age. American Heart Journal 2018;201:95-102.
  • Reisman AM, Robbins BT, Chou DE, et al. Ticagrelor for Refractory migraine/patent foramen Ovale (TRACTOR). An open-label pilot Neurology 2018;91(2):1010-1017.
  • Riaz H, Khan MS, Scheonne AL, Waheed AA, Khan AR, Krasuski RA. Transcatheter closure of patent foramen ovale following cryptogenic stroke: an updated meta-analysis of randomized controlled trials. American Heart Journal 2018;199-44-50.
  • Rigatelli G, Zuin M. Transcatheters for closure of patent foramen ovales. Expert Review of Medical Devices 2018;15(4):277-281.
  • Ryan MJ, Clapp B. Vascular closure devices and thrombosis. In: Topaz O, ed. Cardiovascular Thrombus. From Pathology and Clinical Presentations to Imaging, Pharmacotherapy and Interventions. 1st ed. Cambridge, MA: Academic Press; 2018;30:435-445.
  • Sá MPBO, Oliveira Neto LAP, Nascimento GCSD, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke: meta-analysis of five randomized controlled trials with 3440 patients. Brazilian Journal of Cardiovascular Surgery 2018;33(1):89-98.
  • Saadi A, Saleh M, Wolf J, et al. Complications of percutaneous ASD and pfo closure devices: insights from the Maude database. Presented at the Society for Cardiovascular Angiography & Interventions’ 41st Annual Scientific Sessions; April 25-28, 2018; San Diego, CA. Catheterization & Cardiovascular Interventions 2018;91(Supplement 2):S55-S56. VI-07.
  • Shah AH, Osten M, Benson L, et al. Incidence and outcomes of positive bubble contrast study results after transcatheter closure of a patent foramen ovale. JACC: Cardiovascular Interventions 2018;11(11):1095-1104.
  • Shah R, Nayyar M, Jovin IS, et al. Device closure versus medical therapy alone for patent foramen ovale in patients with cryptogenic stroke: a systematic review and meta-analysis. Annals of Internal Medicine 2018;168(5):335-342.
  • Singh HS, Benson LN, Osten M, Horlick E. Cardiac catheterization in adult congenital heart disease. In: Gatzoulis MA, Webb GD, Daubeney PEF, Diagnosis and Management of Adult Congenital Heart Disease. 3rd ed. Philadelphia, PA: Elsevier; 2018(10):111-150.
  • Sitwala P, Khalid MF, Khattak F, et al. Percutaneous closure of patent foramen ovale in patients with cryptogenic stroke – an updated comprehensive meta-analysis. Cardiovascular Revascularization Medicine. In
  • Smer A, Salih M, Mahfood Haddad T, et al. Meta-analysis of randomized controlled trials on patent foramen ovale closure versus medical therapy for secondary prevention of cryptogenic stroke. American Journal of Cardiology 2018;121(11):1393-1399.
  • Snijder RJR, Suttorp MJ, Ten Berg JM, Post MC. Percutaneous closure of a patent foramen ovale after cryptogenic stroke. Netherlands Heart Journal 2018;26(1):5-12.
  • Snijder RJR, Renes LE, Suttorp MJ, Ten Berg JM, Post MC. Percutaneous patent foramen ovale closure using the Occlutech Figulla device: more than 1,300 patient-years of follow up. Catheterization & Cardiovascular Interventions 2019;93(6):1080-1084.
  • Sommer RJ, Nazif T, Privitera L, Robbins Retrospective review of thienopyridine therapy in migraineurs with patent foramen ovale. Neurology 2018;91(22):1002-1009.
  • Sommer RJ. Beyond cryptogenic stroke: PFO beyond cryptogenic stroke. Presented at the Structural Heart Disease Summit; June 19-23, 2018; Chicago, IL. Available from TCTMD Web site. https://tctmd.com/slide/beyond-iatrogenic-stroke-pfo-closure-migraine-and-more . Published June 23, 2018. Accessed September 4, 2018.
  • Sondergaard L. Data deliverance: updated PFO closure for cryptogenic stroke clinical trial review and guidelines. Available from TCTMD Web site. https://tctmd.com/slide/data- deliverance-updated-pfo-closure-cryptogenic-stroke-clinical-trial-review-and-guidelines . Published June 23, 2018. Accessed September 4, 2018
  • Tang GHL, Cohen M, Dutta T, Undemir C. Afterload mismatch after transcatheter mitral valve repair with MitraClip for degenerative mitral regurgitation in acute cardiogenic shock. Catheterization & Cardiovascular Interventions 2018;92(3):E168-E171.
  • Teshome M, Najib K, Nwabara CC, Akinseys OA, Ibebuogu UN. Patent foramen ovale: a comprehensive review. Current Problems in Cardiology. In
  • Tsivgoulis G, Katsanos AH, Mavridis D, et al. Percutaneous patent foramen ovale closure for secondary stroke prevention: network meta-analysis. Neurology 2018;91(1):e8-e18.
  • West BH, Noureddin N, Mamzhi Y, et al. Frequency of patent foramen ovale and migraine in patients with cryptogenic stroke. Stroke 2018;49(5):1123-1128.
  • Wiktor DM, Carroll JD. ASD closure in structural heart disease. Current Cardiology Reports
    • 2018;20(6).
  • Wiktor DM, Carroll JD. The case for selective patent foramen ovale closure after cryptogenic stroke. Circulation: Cardiovascular Interventions 2018;11:e004152.
  • Xu H, Zhang H, Qin Y, et al. Patent foramen ovale closure versus medical therapy for cryptogenic stroke: an updated meta-analysis. Journal of the Neurological Sciences 2018;390:139-149.
  • Yuan K, Kasner SE. Patent foramen ovale and cryptogenic stroke: diagnosis and updates in secondary stroke prevention. Stroke & Vascular Neurology 2018;3(2):84-91.
  • Zhang XL, Kang LN, Wang L, Xu B. Percutaneous closure versus medical therapy for stroke with patent foramen ovale: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2018;18(1):45.

2017

  • Alhadlaq A, Hussain A, Hancock Friesen C, Dhillon S. Recurrent strokes after Gore Septal Occluder device closure of atrial septal defect. Canadian Journal of Cardiology 2017;33(12):1736.e9-1736.e11.
  • Alkashkari W, Cao QL, Hijazi ZM. Transcatheter closure of atrial septal defects and patent foramen ovale. In: Kern MJ, Lim MJ, Sorajja P, The Interventional Cardiac Catheterization Handbook. 4th ed. Philadelphia, PA: Elsevier; 2017;16:409-437.
  • Anderson JH, Fraint H, Moore P, Cabalka AK, Taggart NW. Novel delivery technique for atrial septal defect closure in young children utilizing the GORE® CARDIOFORM® septal Catheterization & Cardiovascular Interventions 2017;89(7):1232-1238.
  • Atianzar K, Casterella P, Zhang M, Sharma R, Gafoor S. Update on the management of patent foramen ovale in 2017: indication for closure and literature review. US Cardiology Review 2017;11(2):75-79.
  • Bechis MZ, Rubenson DS, Price MJ. Imaging assessment of the interatrial septum for transcatheter atrial septal defect and patent foramen ovale closure. Interventional Cardiology Clinics 2017;6(4):505-524.
  • Butera G, Piazza L, Heles M. PFO «angioplasty»: the preparation of a very stiff and long tunnel for device closure. Catheterization & Cardiovascular Interventions 2017;89(3):480-483.
  • Caso V, van der Worp B, Fischer U. European Stroke Organizational Report. Stroke
    • 2017;48(8):e195-e196.
  • Dalen JE, Alpert JS. Which patent foramen ovales need closure to prevent cryptogenic strokes?
    • American Journal of Medicine 2018;131(3):222-225.
  • de Hemptinne Q, Horlick EM, Osten MD, et al. Initial clinical experience with the GORE® CARDIOFORM ASD Occluder for transcatheter atrial septal defect closure. Catheterization & Cardiovascular Interventions 2017;90(3):495-503.
  • Doleeb S, Patel R, Nfor Platypnea-orthodeoxia secondary to patent foramen ovale: a rare but dramatic cause of respiratory failure. Presented at the 61st Annual Meeting of the Wisconsin Chapter of the American College of Physicians, WI-ACP; July 9-10, 2016; Wisconsin Dells, WI. Wisconsin Medical Society 2017;116(5):269-270.
  • Farb A, Ibrahim NG, Zuckerman BD. Patent foramen ovale after cryptogenic stroke — assessing the evidence for closure. New England Journal of Medicine 2017;377(11):1006-1009.
  • Gaio G, Santoro G, Giordano M, et al. Patent foramen ovale with complex anatomy: comparison of two different devices (amplatzer septal occluder device vs amplatzer PFO occluder device 30/35). Presented at the Congresso Nazionale della Societa Italiana di Cardiologia Interventistica
    • GISE; October 10-13, 2017; Milano, Italy. Giornale Italiano di Cardiologia 2017;18(10):e74.
  • Gillespie M, Javois A, Moore P, Fores T, Paolillo J. Use of the GORE® CARDIOFORM Septal Occluder for transcatheter closure of secundum atrial septal defects: results of the multi-center
    • S. IDE Trial. Presented at the 40th Annual Meeting of the Society for Cardiovascular Angiography and Interventions (SCAI); May 10-13, 2017; New Orleans, LA. Catheterization & Cardiovascular Interventions 2017;89(S2):S18-S19. Abstract O-008.
  • Grant EK, Kim DW, Border WL, Lerakis S, Babaliaros V, Vincent RN. Transseptal anchored vascular plug closure of mitral valve perforation. JACC: Cardiovascular Interventions 2017;10(5):e45-e46.
  • Grohmann J, Wildberg C, Zartner P, et al. Multicenter midterm follow-up results using the gore septal occluder for atrial septal defect closure in pediatric patients. Catheterization & Cardiovascular Interventions 2017;89(7):E226-E232.
  • Hardt SE, Eicken A, Berger F, et al. Closure of patent foramen defects using GORE® CARDIOFORM septal occluder. Catheterization & Cardiovascular Interventions 2017;90(5):824-829.
  • Hijazi ZM, Kenny D. Landmark lecture on interventional cardiology: Interventional cardiac catheterisation for CHD: the past, present, and the future. Presented at the Proceedings of the 2017 7th World Congress of Pediatric Cardiology & Cardiac Surgery (WCPCCS 2017); July
    • 16-21, 2017; Barcelona, Spain. Cardiology in the Young 2017;27(10):1974-1985.
  • Hoole SP, Hernández-Sánchez J, Davies WR, et al. Effects of patent foramen ovale closure on obstructive sleep apnoea syndrome (PCOSA study). Canadian Journal of Cardiology 2017;33(12):1708-1715.
  • Jone PN, Wilson N, Morgan G, Ivy DD, Ross M. Three dimensional echocardiographic guidance of right heart catheterization decreases radiation exposure in atrial septal defect closures. Presented at the 7th World Congress of Pediatric Cardiology & Cardiac Surgery; July 16-21, 2017; Barcelona, Spain. Cardiology in the Young 2017;27(4):S236. Abstract
  • Kamioka N, Iturbe JM, Corrigan F, Lerakis S, Babaliaros Grabbing the transcatheter valve skirt: bail-out technique for valve embolization during valve-in-valve transcatheter mitral valve replacement. JACC: Cardiovascular Interventions 2017;10(9):e175-e176.
  • Kasner SE, Thomassen L, Søndergaard L, Rhodes JF, Larsen CC, Jacobson J. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized Gore REDUCE Clinical Study. International Journal of Stroke 2017;12(9):998-1004.
  • Kasner S, Sondergaard L, Thomassen L, Rhodes J. Baseline characteristics in the Gore Reduce Trial of PFO closure vs. medical therapy compared with prior trials. Presented at the 3rd European Stroke Organisation Conference (ESOC); May 16-18, 2017; Prague, Czech Republic. Poster
  • Kelly BA, Awdish R, Hegab S. Good fences make good neighbors: how an iatrogenic atrial septal defect can impact the pulmonary circulation. American Journal of Respiratory & Critical Care Medicine 2017;195:A6190.
  • Kijima Y, Bokhoor P, Tobis Patent foramen ovale with right atrial septal pouch.
    • Catheterization & Cardiovascular Interventions 2017;89(5):E169-E171.
  • Melikian N, MacCarthy The spectrum of PFO closure devices. Cardiac Interventions Today
    • 2017;11(3):55-57.
  • Mojadidi MK, Mahmoud AN, Elgendy Percutaneous patent foramen ovale closure for cryptogenic stroke: learning from clinical trial and error. Journal of Thoracic Disease 2017;9(11):4222-4225.
  • Nielsen-Kudsk J, Andersen A, Andersen G, et al; REDUCE Investigators. Atrial fibrillation after closure of persistent foramen ovale in the REDUCE clinical trial. European Heart Journal 2018;39:1340.
  • O’Byrne ML, Gillespie MJ, Kennedy KF, Dori Y, Rome JJ, Glatz AC. The influence of deficient retro-aortic rim on technical success and early adverse events following device closure of secundum atrial septal defects: an analysis of the IMPACT Registry®. Catheterization & Cardiovascular Interventions 2017;89(1):102-111.
  • Odunukan OW, Price MJ. Current dataset for patent foramen ovale closure in cryptogenic stroke: randomized clinical trials and observational studies. Interventional Cardiology Clinics 2017;6(4):525-538.
  • Pater C, Brown NM, Goldstein BH. Far from the septum: transcatheter Cardioform Septal Occluder device closure of a descending aortic pseudoaneurysm late after interrupted aortic arch JACC: Cardiovascular Interventions 2017;10(17):e163-e166.
  • Pollak Gore CARDIOFORM right atrial disc inflation – recognition and management. Presented at the 40th Annual Meeting of the Society for Cardiovascular Angiography and Interventions (SCAI); May 10-13, 2017; New Orleans, LA. Catheterization & Cardiovascular Interventions 2017;89(S2):S198. Abstract B-079.
  • Poulin MF, Kavinsky CJ. The approval of PFO closure in the United States. Cardiac Interventions Today 2017;11(3):47-54.
  • Price MJ. Transcatheter closure of patent foramen ovale: devices and technique. Interventional Cardiology Clinics 2017;6(4):555-567.
  • Scheidmann R, Paul T, Sigler M. Transcatheter atrial septal defect closure in an infant (body weight 6.4 kg) using the GORE CARDIOFORM septal occluder (GCSO). Molecular & Cellular Pediatrics 2017;4(1):9.
  • Singh HS, Katchi F, Naidu SS. PFO closure for cryptogenic stroke: a review and clinical treatment algorithm. Cardiology in Review 2017;25(4):147-157.
  • Søndergaard L, Kasner SE, Rhodes JF; Gore REDUCE Study Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. New England Journal of Medicine 2017;377(11):1033-1042.
  • Teleb M, Agrawal H, Albaghdadi A, et al. Combined migraine and Platypnea-Orthodeoxia Syndrome due to combined atrial septal defect and patent foramen ovale. Presented at the American College of Cardiology’s 66th Annual Scientific Session and Expo (ACC.17); March 17-19, 2017. Journal of the American College of Cardiology 2017;69(11)Supplement:2253. Presentation Number: 1169-408.
  • Tobis Addressing the needs of treating congenital heart disease: the influence of deficient retro-aortic rim on technical success and early adverse events following device closure of secundum atrial septal defects: an analysis of the IMPACT Registry®. Catheterization & Cardiovascular Interventions 2017;89(1):112-113.

2016

  • Abu-Tair T, Wiethoff CM, Kehr J, Kuroczynski W, Kampmann C. Transcatheter closure of atrial septal defects using the GORE® Septal Occluder in children less than 10 kg of body weight. Pediatric Cardiology 2016;37(4):778-783.
  • Alkhouli M, Sarraf M, Zack CJ, Holmes DR. Rihal CS. Iatrogenic atrial septal defect following transseptal cardiac interventions. International Journal of Cardiology 2016;209:142-148.
  • Arias EA, Bhan A, Lim ZY, Mullen M. Utility of the Gore Septal Occluder in transcatheter closure of post-myocardial infarct ventricular septal defect: initial experience. JACC: Cardiovascular Interventions 2016;9(21):2259-2261.
  • Butera G, Lovin N, Paola Basile D, Carminati M. Goose-neck snare-assisted transcatheter ASD closure: a safety procedure for large and complex ASDs. Catheterization & Cardiovascular Interventions 2016;87(5):926-930.
  • de Hemptinne Q, Horlick EM, Osten MD, et al. Initial clinical experience with the GORE® CARDIOFORM ASD Occluder for transcatheter atrial septal defect closure. Presented at the 25th edition of the Montréal Live Symposium; June 1-3 2016; Montréal,
  • Dittrich S, Sigler M, Priessmann H. Late complete atrioventricular block after closure of an atrial septal defect with a gore septal occluder (GSO™). Catheterization & Cardiovascular Interventions 2016;87(5):945-950.
  • Eleid MF, Cabalka AK, Williams MR, et al. Percutaneous transvenous transseptal transcatheter valve implantation in failed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcification. JACC: Cardiovascular Interventions 2016;9(11):1161-1174.
  • Hovnanians N, Mojadidi MK, Brandt JC, Tobis Platypnea-orthodeoxia syndrome: a rare cause of unexplained hypoxia. Presented at the American College of Cardiology’s 65th Annual Scientific Session and Expo (ACC.16); April 2-4, 2016; Chicago, IL. Journal of the American College of Cardiology 2016;67(13)Supplement:1084. Presentation Number: 1152-273.
  • Hovnanians N, Mojadidi MK, Brandt JC, Eshtehardi P, Tobis Platypnea-orthodeoxia syndrome: from gastroesophageal reflux to hypoxemia. American Journal of Medicine 2016;129(4):e15-e16.
  • Jalal Z, Hascoet S, Baruteau A-E, et al. Long term complications following transcatheter atrial septal defect closure: a review of the medical literature. Canadian Journal of Cardiology 2016;32(11):1315.e11-1315.e18.
  • Jone PN, Ross MM, Bracken JA, Mulvahill MJ, Di Maria MV, Fagan TE. Feasibility and safety of using a fused echocardiography/fluoroscopy imaging system in patients with congenital heart disease. Journal of the American Society of Echocardiography 2016;29(6):513-521.
  • Kijima Y, Rafique AM, Tobis Patent foramen ovale combined with pulmonary arteriovenous malformation. JACC: Cardiovascular Interventions 2016;9(20):2169-2171.
  • Latson LA. A snare in time-adding a safety mechanism to the Amplatzer Septal
    • Catheterization & Cardiovascular Interventions 2016;87(5):931-932.
  • Lombardi M, Tagliente MR, Pirolo T, Massari E, Milella L, Vairo Feasibility and safety of a new generation of gore septal occluder device in children. Journal of Cardiovascular Medicine 2016;17(Supplement 2):e249-e251.
  • Nassif M, Abdelghani M, Bouma BJ, et al. Historical developments of atrial septal defect closure devices: what we learn from the past. Expert Review of Medical Devices 2016;13(6):555-568.
  • Pearman A, Bugeja L, Nelson M, Szantho GV, Turner MS. An audit of persistent foramen ovale closure in 105 divers. Diving and Hyperbaric Medicine 2015;45(2):94-97.
  • Romero J, Natale A, Engstrom K, Di Biase L. Left atrial appendage isolation using percutaneous (endocardial/epicardial) devices: pre-clinical and clinical experience. Trends in Cardiovascular Medicine 2016;26(2):182-199.
  • Scalise F, Auguadro C, Sorropago G, et al. Long-term contrast echocardiography and clinical follow-up after percutaneous closure of patent foramen ovale using two different atrial septal occluder devices. Journal of Interventional Cardiology 2016;29(4):406-413.
  • Saritas T, Yucel IK, Demir IH, Demir F, Erdem A, Celebi A. Comparison of transcatheter atrial septal defect closure in children, adolescents and adults: differences, challenges and short-, mid- and long-term results. Korean Circulation Journal 2016;46(6):851-861.
  • Shah AH, Osten M, Leventhal A, et al. Percutaneous intervention to treat Platypnea–Orthodeoxia Syndrome: The Toronto JACC: Cardiovascular Interventions 2016;9(18):1928-1938.
  • Suradi HS, Hijazi ZM. Patent foramen ovale: stroke and device closure. Cardiology Clinics
    • 2016;34(2):231-240.
  • Tadros VX, Asgar Transcatheter closure of atrial septal defects. Cardiac Interventions Today
    • 2016;10(2):56-60.
  • Tanase D, Eicken A, Georgiev S, Genz T, Pabst von Ohain J, Ewert Single center experience: retrieval maneuvers of embolized ASD and PFO devices. Presented at the 50th Annual Meeting of the Association for European Paediatric and Congenital Cardiology; June 1-4, 2016; Rome, Italy. Cardiology in the Young 2016;26(S1):S148. P2-75.
  • Tobis JM, Abudayyeh I. Platypnea-Orthodeoxia Syndrome: an overlooked cause of
    • JACC: Cardiovascular Interventions 2016;9(18):1939-1940.
  • Zuin M, Rigatelli G. Secundum atrial septal defects and Methylenetetrahydrofolate Reductase C677T Polymorphism: a special category of ASDs? International Journal of Cardiology 2016;23:139-140.

2015

  • Bissessor N. Current perspectives in percutaneous atrial septal defect closure devices. Medical Devices: Evidence & Research 2015;8:297-303.
  • Boeder NF, Schmitt J, Rixe J, Holger MN. Trapped cardioverter-defibrillator lead after interventional closure of an iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip® system. International Journal of Cardiology 2015;184:412-413.
  • Butera G, Giugno L, Basile D, Chessa M, Saracino A, Carminati M. Angioplasty of a rigid and stiff tunnel in patients with PFO and previous stroke. A new option to prepare the “landing” zone for an occluding device. Presented at the 38th Annual Scientific Sessions of the Society for Cardiovascular Angiography & Interventions’ (SCAI) 2015 Scientific Sessions; May 6-9, 2015; San Diego, CA. Catheterization & Cardiovascular Interventions 2015;85(Supplement 2):S25. Abstract
  • Castaldi B, Vida VL, Argiolas A, et al. Late electrical and mechanical remodeling after atrial septal defect closure in children: surgical versus percutaneous approach. Annals of Thoracic Surgery 2015;100(1):181-186.
  • Cheung G, Søndergaard L. The GORE® Septal Occluder. In: Amin Z, Tobis J, Sievert H, Carroll J, eds. Patent Foramen Ovale. London: Springer Verlag; 2015;17:137-143.
  • Crystal MA, Vincent JA. Septal defect device closure in the pediatric population: a current
    • Current Pediatric Reviews 2015;3(3):237-244.
  • Falanga G, Careji S, Oreto G, Khandheria B, Zito C. How to understand patent foramen ovale clinical significance – Part II: therapeutic strategies in cryptogenic stroke. Journal of Cardiovascular Echography 2015;25(2):46-53.
  • Geis NA, Pleger ST, Katus HA, Hardt SE. Using the GORE® Septal Occluder (GSO) in challenging patent foramen ovale (PFO) anatomies. Journal of Interventional Cardiology 2015;28(2):190-197.
  • Goble JA. The medical device manufacturer’s perspective: L. Gore and Associates, Inc. In: Amin Z, Tobis J, Sievert H, Carroll J, eds. Patent Foramen Ovale. London: Springer Verlag; 2015;26:193-198.
  • Hagler DJ. From FDAs point of view: what is needed to move PFO closure for stroke prevention forward? In: Amin Z, Tobis J, Sievert H, Carroll J, eds. Patent Foramen Ovale. London: Springer Verlag; 2015;25:189-191.
  • Kenny D. Optimal device for children and closure indications in pediatric population. In: Amin Z, Tobis J, Sievert H, Carroll J, eds. Patent Foramen Ovale. London: Springer Verlag; 2015;19:151-155.
  • Lim S, Rhodes J, Paolillo J, Javois A, Hoyer M, Forbes U.S. Multi-centered pivotal trial of the novel GORE® CARDIOFORM Septal Occluder for percutaneous closure of secundum atrial septal defects. Presented at the Pediatric & Adult Interventional Cardiac Symposium (PICS/ AICS 2015); September 18-21, 2015; Las Vegas, NV. Catheterization & Cardiovascular Interventions 2015;86(3):559. Abstract 0059.
  • Mirzaali M, Dooley M, Wynne D, et al. Patent foramen ovale closure following cryptogenic stroke or transient ischaemic attack: long-term follow-up of 301 cases. Catheterization & Cardiovascular Interventions 2015;86(6):1078-1084.
  • Mojadidi MK, Gevorgyan R, Noureddin N, Tobis The effect of patent foramen ovale closure in patients with platypnea-orthodeoxia syndrome. Catheterization & Cardiovascular Interventions 2015;86(4):701-707.
  • Paolillo J, Lim DS, Moore P, Forbes Immediate and one year U.S. IDE trial results of the new GORE® CARDIOFORM Septal Occluder for transcatheter closure of secundum atrial septal defects. Presented at the Twenty-Seventh Annual Symposium of Transcatheter Cardiovascular Therapeutics (TCT); October 11-15, 2015; San Francisco, CA. Journal of the American College of Cardiology 2015;66(15)Supplement:B13. TCT-31.
  • Pearman A, Bugeja L, Nelson M, Szantho GV, Turner MS. An audit of persistent foramen ovale closure in 105 divers. Diving and Hyperbaric Medicine 2015;45(2):94-97.
  • Pedersen TA, Larsen SH, Nielsen-Kudsk JE. Closure of a patent foramen ovale in patients with platypnoea-orthodeoxia: a rare and overlooked cause of dyspnoea and hypoxaemia. Scandinavian Cardiovascular Journal 2015;49(6):357-360.
  • Reinthaler M, Aggarwal SK, Mert A, et al. Closure of long-tunnel PFOs with the Coherex Flatstent EF – a tailored approach. Journal of Invasive Cardiology 2015;27(9):E190-E195.
  • Rhodes JF Jr, Kasner SE. The Gore REDUCE Clinical In: Amin Z, Tobis J, Sievert H, Carroll J, eds. Patent Foramen Ovale. London: Springer Verlag; 2015;23:181-184.
  • Schneider H, Sigler M, Krause U, Preuss HC, Paul Residual shunt after occlusion of an atrial septal defect with the GORE HELEX Septal Occluder: Closure with the newer GORE Septal Occluder. Presented at the Pediatric & Adult Interventional Cardiac Symposium (PICS/AICS 2015); September 18-21, 2015; Las Vegas, NV. Catheterization & Cardiovascular Interventions 2015;86(3):546. Abstract 0021.
  • Sganzerla P, Rondi M, Pavone A, et al. Clinical performance of the new Gore Septal Occluder in patent foramen ovale closure: a single-center experience. Journal of Invasive Cardiology 2015;27(9):430-434
  • Thomson JDR, Qureshi SA. Device closure of secundum atrial septal defect’s and the risk of cardiac erosion. Echo Research & Practice 2015;2(4):R73-R78.
  • Thomson JDR. Step-by-step closure of atrial septal defects (ASDs). In: Butera G, Chessa M, Eicken A, Thomson J, eds. Cardiac Catheterization for Congenital Heart Disease: From Fetal Life to Adulthood. Milan, Italy: Springer-Verlag Italia; 2015;(26):421-447.
  • Tobis J, Abudayyeh I. New devices and technology in interventional cardiology. Journal of Cardiology 2015;65(1):5-16.
  • Verma DR, Khan MF, Tandar A, et al. Nickel elution properties of contemporary interatrial shunt closure devices. Journal of Invasive Cardiology 2015;27(2):99-104.

2014

  • Ben Moussa N, Cinteza E, Giugno L, et al. Echocardiographic guidance of percutaneous patent formen ovale closure: comparison of tranesophageal versus rotational intracardiac echocardiography: a single center experience. Presented at the 18th Annual Meeting of the European Association of Echocardiography (EUROECHO 2014); December 3-6, 2014; Vienna, Austria. European Heart Journal Cardiovascular Imaging 2014;15(Supplement 2):ii53. Abstract 325.
  • Bhan A, Clapp B. Review of data and discussion – who should undergo patent foramen ovale closure in 2014? Interventional Cardiology Review 2014;9(2):115-120.
  • Darsaklis K, Freixa X, Asgar A, et al. A novel system for transcatheter closure of patent foramen ovale: clinical and echocardiographic outcome comparison with other contemporary devices. Canadian Journal of Cardiology 2014;30(6):639-646.
  • Freixa X, Arzamendi D, Tzikas A, et al. Cardiac procedures to prevent stroke: patent foramen ovale closure / left atrial appendage occlusion. Canadian Journal of Cardiology 2014;30(1):87-95.
  • Grohmann J, Höhn R, Fleck T, Schmoor C, Stiller B. Transcatheter closure of atrial septal defects in children and adolescents: single-center experience with the GORE® Septal Occluder. Catheterization & Cardiovascular Interventions 2014;84(6):E51-E57.
  • Kasner S; Gore REDUCE Study Investigators. GORE HELEX Septal Occluder / GORE Septal Occluder and antiplatelet medical management for reduction of recurrent stroke or imaging- confirmed TIA in patients with patent foramen ovale (PFO) _ The Gore REDUCE Clinical Poster presented at the International Stroke Conference 2014; February 12-14, 2014; San Diego, CA. CT P5.
  • Knerr M, Bertog S, Vaskelyte L, Hofmann I, Sievert H. Results of percutaneous closure of patent foramen ovale with the GORE ® septal occluder. Catheterization & Cardiovascular Interventions 2014;83(7):1144-1151.
  • Larzon Obstacles in treating chronic type B dissection. Presented at the Leipzig Interventional Course – LINC 2014; January 28-31, 2014; Leipzig, Germany.
  • Rekhraj S, Vassiliou V, Orzalkiewicz M, et al. Does the Gore Septal Occluder offer excellent closure of all PFO phenotypes when guided by 3D imaging? Presented at the British Cardiovascular Society Annual Conference; June 2-4, 2014; Manchester Central, Heart 2014;100(Supplement 3):A82-A83. Abstract 140.
  • Rigatelli G, Dell’avvocata F, Tarantini G, Giordan M, Cardaioli P, Nguyen Clinical, hemodynamic, and intracardiac echocardiographic characteristics of secundum atrial septal defects-related paradoxical embolism in adulthood. Journal of Interventional Cardiology 2014;27(6):542-547.
  • Rigatelli G, Dell’Avvocata F, Giordan M, et al. Usefulness of intracardiac echocardiography with a mechanical probe for catheter-based interventions: a 10-year prospective registry. Journal of Clinical Ultrasound 2014;42(9):534-543.
  • Saylam GS, Azbarlas N, Karagaz T, et al. Transcatheter closure of atrial septal defects using the new Gore® septal occluder in children: initial results from a multicentre Presented at the 5th Congress of the Asia Pacific Pediatric Cardiac Society; March 6-9, 2014; New Delhi, India. Annals of Pediatric Cardiology 2014:7(Supplement 1):S56-S57. OA 103.
  • Smith B, Thomson J, Crossland D, Spence MS, Morgan GJ. UK multicenter experience using the gore septal occluder (GSOTM ) for atrial septal defect closure in children and adults. Catheterization & Cardiovascular Interventions 2014;83(4):581-586.
  • Thomson JD, Hildick-Smith D, Clift P, et al. Patent foramen ovale closure with the Gore Septal Occluder (GSO): initial UK experience. Catheterization & Cardiovascular Interventions 2014;83(3):467-473.
  • Wan A, Vijarnsorn C, Rutledge J. Initial experience with the GORE® Septal Occluder for Atrial septal defect closure in children. Presented at the Canadian Cardiovascular Congress 2014 – 67th Annual Meeting of the Canadian Cardiovascular Society; October 25-28, 2014; Vancouver, British Columbia. Canadian Journal of Cardiology 2014;30(10)Supplement: S170-S171.
  • Wilson W, Osten M, Benson L, Horlick E. Evolving trends in interventional cardiology: endovascular options for congenital disease in adults. Canadian Journal of Cardiology 2014;30(1):75-86.

2013

 

  • Butera G, Saracino A, Danna P, Sganzerla P, Chessa M, Carminati M. Transcatheter PFO closure with GORE® septal occluder: early and mid-term clinical results. Catheterization & Cardiovascular Interventions 2013;82(6):944-949.
  • Cilingiroglu M, Marmagkiolis K. Percutaneous closure of multiple atrial septal defects: do we have the ideal device yet? Catheterization & Cardiovascular Interventions 2013;81(7):1243.
  • Fallavollita L, Massini C. Percutaneous closure of a patent foramen ovale with a Gore Septal Occluder device in a young woman. Cath Lab Digest 2013;21(9):48-49.
  • Freixa X, Garceau P, Asgar First experience with the new GORE Septal Occluder for the closure of multiple atrial septal defects. Catheterization & Cardiovascular Interventions 2013;81(7):1238-1242.
  • Freixa X, Ibrahim R, Chan J, et al. Initial clinical experience with the GORE septal occluder for the treatment of atrial septal defects and patent foramen ovale. EuroIntervention 2013;9(5):629-635.
  • Freixa X, Arzamendi D, Tzikas A, et al. Cardiac procedures to prevent stroke: patent foramen ovale closure / left atrial appendage occlusion. Canadian Journal of Cardiology 2014;30(1):87-95.
  • Kwong JS, Lam YY, Yu Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials. International Journal of Cardiology 2013;168(4):4132-4138.
  • Lockhart CJ, Johnston NG, Spence MS. Experience using the new GORE Septal Occluder at the Catheterization & Cardiovascular Interventions 2013;81(7):1244-1248.
  • MacDonald ST, Daniels MJ, Ormerod OJ. Initial use of the new GORE® Septal Occluder in patent foramen ovale closure: implantation and preliminary results. Catheterization & Cardiovascular Interventions 2013;81(4):660-665.
  • Musto C, Cifarelli A, Fiorilli R, et al. Comparison between the new Gore septal and Amplatzer devices for transcatheter closure of patent foramen ovale. Short- and mid-term clinical and echocardiographic outcomes. Circulation Journal 2013;77(12):2922-2927.
  • Nyboe C, Hjortdal VE, Nielsen-Kudsk JE. First experiences with the GORE® Septal Occluder in children and adults with atrial septal defects. Catheterization & Cardiovascular Interventions 2013;82(6):929-934.
  • Sievert H, Hofmann I, Vaskelyte L, Bertog S, Gafoor S, Lam S. What is in the pipeline for PFO closure? Devices and data. Presented at the Twenty-Fifth Annual Symposium Transcatheter Cardiovascular Therapeutics (TCT); October 27-November 1, 2013; San Francisco,
  • Singh HS, Horlick E, Osten M, Benson LN. Preview Interventional cardiology in adults with congenital heart disease. Nature Reviews Cardiology 2013;10(11):662-678.
  • Søndergaard L, Loh PH, Franzen O, Ihlemann N, Vejlstrup N. The first clinical experience with the new GORE® septal occluder (GSO). Eurointervention 2013;9(8):959-963.

2012

  • Butera G, Danna P, Musto C, et al. GORE® Septal Occluder: early clinical results. Congenital Cardiology Today 2012;10(6):1, 3-7.
  • Butera G, Danna P, Musto C, et al. GORE® SEPTAL OCCLUDER: early clinical results. Presented at the 46th Annual Meeting of the Association for European Paediatric and Congenital Cardiology, AEPC with joint sessions with the Japanese Society of Pediatric Cardiology and Cardiac Surgery; May 23-26, 2012; Istanbul, Cardiology in the
    • Young 2012;22(Supplement S1):S150. Abstract P-266.
  • Khan M, Tandar A, Verma D, et al. UNES (Utah Nickel Elution Studies). Abstract presented at the TCT 2012: Transcatheter Cardiovascular Therapeutics 24th Annual Scientific Symposium; October 22-26, 2012; Miami, FL. Journal of the American College of Cardiology 2012;60(17)Supplement B:B226. TCT-776.
  • Freixa X, Ibrahim R, Chan J, Asgar The Gore Septal Occluder: initial experience. Abstract presented at the Canadian Cardiovascular Congress 2012 – 65th Annual Meeting of the Canadian Cardiovascular Society; October 27-31, 2012; Toronto, Ontario, Canada. Canadian Journal of Cardiology 2012;28(5)Supplement:S407. Abstract 80.
  • Loh PH, Cholteesupachai J, Jensen T, Franzen O, Søndergaard L. Immediate and short-term outcome of the Gore Septal Occluder® (GSO) in patent foramen ovale and atrial septal defect closure – early clinical experience. Presented at the 46th Annual Meeting of the Association for European Paediatric and Congenital Cardiology, AEPC with joint sessions with the Japanese Society of Pediatric Cardiology and Cardiac Surgery; May 23-26, 2012; Istanbul, Cardiology in the Young 2012;22(Supplement S1):S157. Abstract P-284.
  • MacDonald S, Daniels M, Ormerod O. Initial use of the new Gore® Septal Occluder in patent foramen ovale closure. Presented at the Society for Cardiovascular Angiography &Interventions’ 35th Annual Scientific Sessions; May 9-12, 2012; Las Vegas, Catheterization & Cardiovascular Interventions 2012;79(S1):S14. Abstract D-014.
  • Tobis J, Shenoda M. Percutaneous treatment of patent foramen ovale and atrial septal defects.
    • Journal of the American College of Cardiology 2012;60(10):1722-1732.

 

 

6/13/2019 ds

Products listed may not be available in all markets pending regulatory clearance.

Some articles describe indications that may not be approved in the United States and /or other nations worldwide

GORE®, CARDIOFORM, HELEX®, and designs are trademarks of W. L. Gore & Associates